RG1068 (Synthetic Human Secretin) ( DrugBank: Human secretin, Secretin, Synthetic human secretin )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 298 | Hereditary pancreatitis | 2 |
298. Hereditary pancreatitis
Clinical trials : 98 / Drugs : 180 - (DrugBank : 57) / Drug target genes : 53 - Drug target pathways : 142
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT00620919 (ClinicalTrials.gov) | February 2008 | 22/1/2008 | Secretin Enhanced Multidetector CT Pancreatography for Evaluation of Known or Suspected Chronic Pancreatitis | RG1068 (Synthetic Human Secretin) Enhanced Multidetector CT Pancreatography: Evaluation of the Pancreatic Duct in Patients With Known or Suspected Chronic Pancreatitis | Chronic Pancreatitis | Drug: RG1068 (Synthetic Human Secretin) | Massachusetts General Hospital | NULL | Terminated | 18 Years | 90 Years | Both | 0 | Phase 1 | United States |
| 2 | NCT00621283 (ClinicalTrials.gov) | February 2008 | 22/1/2008 | Secretin Enhanced MRCP for Evaluation of Pancreatic Duct in Pediatric Population | RG1068 (Synthetic Human Secretin) Enhanced MRCP for Morphological Evaluation of the Pancreatic Duct in the Pediatric Population | Acute Recurrent Pancreatitis;Chronic Pancreatitis | Drug: RG1068 (Synthetic Human Secretin) | Massachusetts General Hospital | NULL | Terminated | 2 Years | 18 Years | Both | 0 | Phase 1 | United States |